Markets
GSK

Bristol-Myers Inks Deal to Sell HIV Pipeline to ViiV Healthcare

Bristol-Myers Squibb CompanyBMY announced that it has entered into two agreements (for late-stage HIV candidates, and for discovery and pre-clinical HIV candidates) with global HIV company, ViiV Healthcare, to divest its HIV pipeline. The deal is expected to close in the first half of 2016.

As per the terms of the agreement, Bristol-Myers will get upfront payments totaling $350 million, and potential development and regulatory milestone payments of up to $518 million for its late-stage HIV candidates; and up to $587 million for discovery and pre-clinical candidates. Additionally, the company will get tiered royalties once the candidates are approved. ViiV Healthcare will also pay sales-based milestone payments of up to $750 million for each late-stage candidate and up to $700 million for each of its discovery and pre-clinical candidates.

We not that Bristol-Myers retains rights to its marketed HIV drugs - Reyataz, Evotaz, Sustiva and Atripla.

How will ViiV Healthcare Benefit from the Deal?

The deal will add Bristol-Myers' fostemsavir (BMS-663068, phase III - for heavily treatment experienced patients) and maturation inhibitors, BMS-955176 (phase IIb - for both treatment-naive and treatment experienced HIV patients) and BMS-986173, among others to ViiV Healthcare's pipeline.

These candidates will complement ViiV Healthcare's existing portfolio. The company plans to evaluate multiple opportunities for their development as combination therapies. We note that ViiV Healthcare, a company focused on the treatment of HIV, was established by GlaxoSmithKline GSK and Pfizer PFE in 2009. After certain amendments in Oct 2012, Shionogi joined as a shareholder.

Bristol-Myers currently carries a Zacks Rank #2 (Buy). A couple of other well-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN and Pfizer. Achillion sports a Zacks Rank #1 (Strong Buy), while Pfizer carries the same rank as Bristol-Myers.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK BMY PFE

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More